Pioglitazone and Losartan Provides Additional Renoprotection

Shanghai Jiao Tong University School of Medicine60 enrolled

Overview

Peroxisomal proliferator-activated receptor agonist pioglitazone and rosiglitazone are currently used in the treatment of type 2 diabetes, as efficient insulin sensitizers alone or in combination with insulin.angiotensin II receptor antagonist losartan reduced the levels of proteinuria.Whether Combination therapy with pioglitazone and losartan provides additional renoprotection in subjects with type 2 diabetic nephropathy,it's worth researching.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Type 2 Diabetes Diabetic Nephropathy

Interventions

pioglitazone+losartanDRUG

Pioglitazone (30 mg/daily) losartan (100 mg daily)

losartanDRUG

losartan (100 mg daily)

Eligibility

Sex: ALLMin age: 32 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Fasting plasma glucose (FPG) level of 3.3-9.0mmol/L * 2h plasma glucose level of 7.5-13 mmol/L * serum creatinine values between 190 and 660umol/L * Two occasions of a ratio of urinary albumin to urinary creatinine≥300 or 24 hours urinary protein concentration is \>150mg * Informed consent Exclusion Criteria: * Type1 diabetes or nondiabetic renal disease * abnormal liver function * heart dysfunction

Outcomes

Primary Outcomes

Renal function

fasting glucose, HbA 1c , Scr, 24-hour urinary protein excretion, and endogenous creatinine clearance (Ccr)

Time frame: 12 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.